Credit Suisse analyst A.J. Rice reiterated a Sell rating on Aveanna Healthcare Holdings (AVAH – Research Report) today and set a price target of $1.00. The company’s shares closed yesterday at $1.09.
Rice covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, ACADIA Pharmaceuticals, and Amedisys. According to TipRanks, Rice has an average return of 9.7% and a 59.79% success rate on recommended stocks.
In addition to Credit Suisse, Aveanna Healthcare Holdings also received a Sell from Bank of America Securities’s Joanna Gajuk in a report issued yesterday. However, today, Raymond James downgraded Aveanna Healthcare Holdings (NASDAQ: AVAH) to a Hold.
See Insiders’ Hot Stocks on TipRanks >>
AVAH market cap is currently $202.6M and has a P/E ratio of -0.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aveanna Healthcare Holdings Inc is a diversified home care platform focused on providing care to medically complex, high-cost patient populations. It directly address the most pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home, the lower cost care setting preferred by patients.
Read More on AVAH:
- Aveanna Healthcare Holdings Announces First Quarter 2023 Financial Results
- Aveanna Announces First Quarter 2023 Earnings Release Date and Conference Call
- Aveanna price target lowered to $3 from $4 at Raymond James
- Aveanna price target lowered to $1.70 from $3 at Deutsche Bank
- Aveanna sees FY23 revenue at least $1.84B, consensus $1.84B
